EUVIMEDEUVIMED entdecken
Klinische Studie

Glycosylation of ascites-derived exosomal CD133: a potential prognostic biomarker in patients with advanced pancreatic cancer

Takahiko Sakaue, Hironori Koga, Hideki Iwamoto, Toru Nakamura, Yu Ikezono, Mitsuhiko Abe, Fumitaka Wada, Atsutaka Masuda, Toshimitsu Tanaka, Masaru Fukahori, Tomoyuki Ushijima, Yuutarou Mihara und 6 weitere

Medical Molecular Morphology · 2019-12 · 52 (4) · 198-208

DOI: 10.1007/s00795-019-00218-5 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Medical Molecular Morphology, online erschienen am 25.02.2019. Verfasst von Takahiko Sakaue und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: The Promotion and Mutual Aid Corporation for Private Schools of Japan (PMAC) Scholarship Fund for Young Researchers.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer cells surviving in ascites exhibit cancer stem cell (CSC)-like features. This study analyzed the expression of the CSC marker CD133 in the ascites-derived exosomes obtained from patients with unresectable pancreatic cancer. In addition, inverse correlation of CD133 expression with prognosis was examined. Of the 133 consecutive patients, 19 patients were enrolled in the study. Exosomes derived from the malignant ascites demonstrated higher density and wider variation in size than those from non-malignant ascites. Western blot revealed enhanced expression of CD133 in exosomes obtained from patients with pancreatic cancer compared to those obtained from patients with gastric cancer or liver cirrhosis. A xenograft mouse model with malignant ascites was established by intraperitoneal inoculation of human pancreatic cancer cells in nude mice. Results obtained from the human study were reproduced in the mouse model. Statistically significant equilateral correlation was identified between the band intensity of CD133 in western blot and overall survival of patients. Lectin microarray analyses revealed glycosylation of CD133 by sialic acids as the major glycosylation among diverse others responsible for the glycosylation of exosomal CD133. These findings suggest that highly glycosylated CD133 in ascites-derived exosomes as a potential biomarker for better prognosis of patients with advanced pancreatic cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AC133 AntigenAnimalsAscitesBiomarkers, TumorCell Line, TumorExosomesGlycosylationHeLa CellsHumansMaleMiceMice, Inbred BALB CMice, NudeNeoplastic Stem CellsPC-3 CellsPancreatic NeoplasmsPrognosisStomach Neoplasms

Stichwörter der Autor:innen

AscitesCD133ExosomeGlycosylationPancreatic cancerPrognostic biomarker

Substanzen

AC133 AntigenBiomarkers, TumorPROM1 protein, human

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
  • Liver Cancer Research Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume, Japan.
  • Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan. hirokoga@med.kurume-u.ac.jp.
  • Liver Cancer Research Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume, Japan. hirokoga@med.kurume-u.ac.jp.
  • Center for Multidisciplinary Treatment of Cancer, Kurume University Hospital, Kurume, Japan.
  • Department of Pathology, Kurume University School of Medicine, Kurume, Japan.

Förderung

  • The Promotion and Mutual Aid Corporation for Private Schools of Japan (PMAC) Scholarship Fund for Young Researchers

Zitieren

APA

Sakaue, T., Koga, H., Iwamoto, H., Nakamura, T., Ikezono, Y., Abe, M., Wada, F., Masuda, A., Tanaka, T., Fukahori, M., Ushijima, T., Mihara, Y., Naitou, Y., Okabe, Y., Kakuma, T., Ohta, K., Nakamura, K. I., & Torimura, T. (2019). Glycosylation of ascites-derived exosomal CD133: a potential prognostic biomarker in patients with advanced pancreatic cancer. Medical Molecular Morphology, 52(4), 198-208. https://doi.org/10.1007/s00795-019-00218-5

Vancouver

Sakaue T, Koga H, Iwamoto H, Nakamura T, Ikezono Y, Abe M, et al. Glycosylation of ascites-derived exosomal CD133: a potential prognostic biomarker in patients with advanced pancreatic cancer. Medical Molecular Morphology. 2019;52(4):198-208. doi:10.1007/s00795-019-00218-5

BibTeX
@article{Sakaue2019,
  author = {Sakaue, Takahiko and Koga, Hironori and Iwamoto, Hideki and Nakamura, Toru and Ikezono, Yu and Abe, Mitsuhiko and Wada, Fumitaka and Masuda, Atsutaka and Tanaka, Toshimitsu and Fukahori, Masaru and Ushijima, Tomoyuki and Mihara, Yuutarou and Naitou, Yoshiki and Okabe, Yoshinobu and Kakuma, Tatsuyuki and Ohta, Keisuke and Nakamura, Kei-Ichiro and Torimura, Takuji},
  title = {Glycosylation of ascites-derived exosomal CD133: a potential prognostic biomarker in patients with advanced pancreatic cancer},
  journal = {Medical Molecular Morphology},
  year = {2019},
  volume = {52},
  number = {4},
  pages = {198--208},
  doi = {10.1007/s00795-019-00218-5}
}
Kostenlos starten →